Biomarker Europe Summit 2016

Organizer: GTCbio

Start date: October 5th, 2016 End date: October 7th, 2016

biomark ereurope summit

GTCbio would like to invite you to attend our Biomarker Summit Europe 2016 on October 5-7, 2016  in Berlin, Germany!

The summit will address the latest developments in the biomarker arena from discovery to translation to commercialization. Presentations span across multiple disciplines and cover topics such as discovery and validation strategies, the challenges of clinical translation, novel technologies including next-generation sequencing, companion diagnostics, the health economics value of biomarkers, reimbursement environment, and perspective on cell free biomarkers for disease diagnostics. Scientific data, case studies and discussions will be facilitated by key representatives from pharma, biotech, academia and the public sector.

Biomarker Summit Europe 2016 consists of four conferences including joint sessions:

Conference: 10th Biomarkers in Drug Discovery & Development
Conference: 5th Biomarkers in Diagnostics
Conference: Biomarkers in Clinical Development & Clinical Trials
Conference: Cell-Free Biomarkers

10th Biomarkers in Drug Discovery & Development
I. Biomarker Discovery & Identification Strategies
II. Biomarkers from Qualification to Validation
III. Biomarkers of Translational Medicine: Safety, PK/PD, & Efficacy
IV. Biomarkers in Personalized Medicine
V. Big Data Analytics for Biomarkers Development

5th Biomarkers in Diagnostics
I. Novel Diagnostic Technologies
II. New Diagnostic Biomarkers & Their Development
III. Joint Session: Clinical Utility of Diagnostic & Screening Biomarkers
IV. Joint Session: Companion Diagnostics Development & Commercialization
V. Joint Session: Health Economics Value of Biomarkers & Reimbursement Environment
VI. Joint Session: Regulatory Considerations in Clinical Dx

Biomarkers in Clinical Development & Clinical Trials
I. Joint Session: Clinical Utility of Diagnostic & Screening Biomarkers
II. Joint Session: Companion Diagnostics Development & Commercialization
III. Joint Session: Health Economics Value of Biomarkers & Reimbursement Environment
IV. Joint Session: Regulatory Considerations in Clinical Dx
V. Clinical Trials & Developments
VI. Biomarkers & Surrogate Endpoints for Clinical Trials

Cell-Free Biomarkers
I. Circulating Biomarkers Overview
II. Cell-free DNA & RNA Technologies & Their Platforms
III. Clinical Applications of Cell-Free DNA & RNA in Disease Diagnosis & Management
IV. New Developments in Cell-Free Biomarkers
V. Exosomes in Diagnosis, Treatment, & Disease Management

Event Website:

We hope to see you there!


Leave a Reply